Technetium succimer
As of the edition of 20 October 2026, Technetium succimer is a small molecule: marketed, first approved in 1982 (US); acts on A2M; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Mpi Dmsa Kidney Reagent
- First approved
- 18 May 1982 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Theragnostics; 2 holders in all
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| A2M | Alpha-2-macroglobulin | P01023 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GE Healthcare | Applicant | 1982 to now |
| Theragnostics | Later holder | 2022 to now |